S-1/A: Xcelerate, Inc. Files Amendment #2 to Form S-1, Eyes Nasdaq Listing and Public Offering

Xcelerate, Inc. is moving forward with its plans for a public offering and Nasdaq listing, as detailed in its latest S-1/A filing.

Summary

• Xcelerate, Inc., a healthcare services and products company, filed an amendment to its Form S-1 registration statement.
• The company is pursuing a public offering of its common stock and aims to list on the Nasdaq Capital Market under the symbol XCRT.
• Xcelerate focuses on three business areas: virtual health technology in developing countries, formulation and marketing of skincare products, and owning/licensing medical equipment rights.
• A 1-for-[] reverse stock split is expected to occur immediately following the effective date of the registration statement.
• The company intends to use the net proceeds for ESN Group product development and marketing, expansion of the Afiya project, and general corporate purposes.
• The company faces risks including a 'going concern' opinion from its independent accountants, a limited operating history, and the need for additional capital.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is pursuing growth opportunities and has made strategic acquisitions, it also faces significant financial challenges and risks, including a 'going concern' opinion and the need for additional capital.

Positives

• The company has agreements with two hospitals in Tanzania to provide its virtual health technology.
• The company acquired a majority interest in ESN Group, a skincare and haircare product company, in July 2023.
• The company owns and licenses rights to various forms of medical equipment and technology.

Negatives

• The company's independent accountants have expressed a 'going concern' opinion.
• The company has a limited operating history and may never achieve profitability.
• The company may require additional capital to implement its business plan, which may have a dilutionary effect on existing shareholders.

Risks

• The company's financial statements have been prepared assuming that it will continue as a going concern.
• The company has a minimal operating history and no revenues or earnings from operations.
• The company may require additional funding to satisfy its future capital needs, which may not be available.
• The company is an early-stage company with a business model and marketing strategy still being developed and largely untested.
• The company's officers and directors may be engaged in a range of business activities resulting in conflicts of interest.
• The company's expansion into new markets may present increased risks due to its unfamiliarity with those areas and its target customers unfamiliarity with its brand.
• The company may be subject to legal claims against it or claims by it which could have a significant impact on its resulting financial performance.
• The beauty business is highly competitive and if the company is unable to compete effectively its results will suffer.
• The virtual care market is immature and volatile, and if it does not continue to develop, the growth of the company's business will be harmed.
• An active, liquid trading market for the company's common stock does not currently exist and may not develop after this offering, and as a result, you may not be able to sell your common stock at or above the public offering price, or at all.
• The proposed Reverse Stock Split may decrease the liquidity of the company's common stock.
• The company's Chief Executive Officer has the ability to significantly influence or control matters requiring a shareholder vote and other shareholders may not have the ability to influence corporate transactions.
• The company's stock price could be extremely volatile and may decline substantially from the public offering price.
• The company may issue additional shares of its common stock or create a new class of securities, including issuance of a new class of preferred stock if it needs to raise additional capital.
• Florida law, the company's Articles of Incorporation and its by-laws provides for the indemnification of its officers and directors at its expense, and correspondingly limits their liability, which may result in a major cost to the company and hurt the interests of its shareholders because corporate resources may be expended for the benefit of officers and/or directors.
• The company does not intend to pay cash dividends on any investment in the shares of stock of our Company and any gain on an investment in our Company will need to come through an increase in our stocks price, which may never happen.
• A significant portion of the company's total outstanding shares are restricted from immediate resale but may be sold into the market in the future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.
• The requirements of being a public company may strain the company's resources, divert management's attention and affect its ability to attract and retain executive management and qualified board members.
• The company is classified as an emerging growth company as well as a smaller reporting company and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.

Future Outlook

The company anticipates generating revenues from its agreements with hospitals in Tanzania approximately 3-4 months following the closing of this offering. The company expects to incur losses in the foreseeable future.

Industry Context

The document highlights Xcelerate's participation in the growing virtual health and skincare markets, both of which are experiencing increased demand and competition. The company's focus on developing countries and natural products aligns with current industry trends.

Comparison to Industry Standards

• The document mentions CeraVe, Eucerin, and Cetaphil as leading skincare products, positioning Ceramedx as a natural alternative.
• The document compares ASA to Babylon (Rwanda only), Agha Khan Pigia Daktar, iPath plus, Lyft Plus and Ada Health.
• The document states that ASA compares favorably to its competitors due to Dr. Ellegala and Mr. Words considerable history and involvement in healthcare in the region, as well as its plans to provide a much wider range of services including digital front door, augmented reality medical measurements, patient data collection, scribing, telemedicine, AI assisted diagnosis and treatment, drug and non-drug treatment, EMR integration, closed loop follow up and criteria based audit, customized for country context and US patient protected AI and AR.

Related Party Transactions

• The funding for the company's operations has been provided by Michael OShea, the CEO, and from shareholders in the form of interest free demand loans.
• In February 2021, the Company and Mr. OShea mutually agreed to redeem all of our issued and outstanding Series A Preferred Shares back to us.
• In September 2020, the company entered into an exclusive world-wide license agreement with Consulting Group of Jocassee, Inc., Pickens, South Carolina, for use of the technology in the medical field, which includes US Patent #10,718586 and any continuations, divisonals and any additional patent applications, patents, continuations and divisonals that are based on the metal matrix as used in the initial patent, except for use in medical applications.
• Our principal place of business is provided to us by a company owned and controlled by Mr. OShea, rent free.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional shares.
• Employees may be affected by the company's ability to secure funding and implement its business plan.
• Customers may benefit from the company's development of new products and services.
• Suppliers may be affected by the company's ability to maintain its operations and meet its obligations.
• Creditors may be affected by the company's ability to repay its debts.

Next Steps

• The company intends to list on the Nasdaq Capital Market.
• The company intends to use the net proceeds for ESN Group product development and marketing, expansion of the Afiya project, and general corporate purposes.

Key Dates

Keywords

public offering, Nasdaq, virtual health, skincare, medical equipment, reverse stock split, Afiya, ESN Group, Xcelerate, healthcare